Monogram Health announced it has closed on $375 million of new funding, reports Healthcare IT Today. This round included investments from leading strategic investors CVS Health, Cigna Ventures, Humana, Memorial Hermann Health System, and SCAN, as well as from both new and existing investors including TPG Capital, Frist Cressey Ventures, Heritage Group, Pura Vida Investments, and Norwest Venture Partners, among others.
Monogram is a value-based specialty provider of in-home evidence-based care and benefit management services for patients living with polychronic conditions, including chronic kidney and end-stage renal disease.
The company will use the funding proceeds to continue to support the rapid and widespread deployment of its in-home kidney and polychronic care delivery model as well as its technology-driven array of evidence-based clinical services, which include complex case and disease management, utilization management, and medication therapy management. Read more.
